Comparative Pharmacology
Head-to-head clinical analysis: CINACALCET HYDROCHLORIDE versus SENSIPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CINACALCET HYDROCHLORIDE versus SENSIPAR.
CINACALCET HYDROCHLORIDE vs SENSIPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allosteric activator of the calcium-sensing receptor (CaSR) on parathyroid chief cells, increasing sensitivity to extracellular calcium and reducing parathyroid hormone (PTH) secretion.
Calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR) on parathyroid chief cells, increasing its sensitivity to extracellular calcium, thereby reducing parathyroid hormone (PTH) secretion.
30 mg orally once daily, titrate every 2-4 weeks to a maximum of 180 mg once daily to achieve target intact parathyroid hormone (iPTH) level.
30 mg orally once daily, titrated every 2-4 weeks to a maximum of 180 mg once daily to achieve target iPTH reduction.
None Documented
None Documented
Terminal elimination half-life: 30–40 hours in patients with normal renal function; prolonged to 42–83 hours in moderate to severe hepatic impairment. Steady-state reached within 7 days.
The terminal elimination half-life of cinacalcet is approximately 30 to 40 hours in patients with normal renal function, supporting once-daily dosing. Steady-state concentrations are achieved within 7 days.
Renal: 80% (as metabolites), Fecal: 15%, Biliary: negligible.
Renal excretion of unchanged drug and metabolites accounts for approximately 84% of the administered dose; fecal excretion accounts for approximately 11%. The primary metabolic pathway is CYP3A4-mediated oxidation, followed by glucuronidation.
Category C
Category C
Calcimimetic
Calcimimetic